Literature DB >> 33269892

Case Series: Novel Utilization of Rho-Kinase Inhibitor for the Treatment of Corneal Edema.

Emma Davies1.   

Abstract

PURPOSE: To describe 3 cases of corneal clearance after the use of topical rho-kinase inhibitor, netarsudil, in the setting of endothelial cell dysfunction in comparison to one case without corneal clearance after the use of netarsudil.
METHODS: Four patients presenting to a busy academic clinical corneal practice with visual complaints from corneal edema secondary to endothelial cell dysfunction were treated with topical netarsudil one drop daily in the affected eye.
RESULTS: Corneal clearance was observed in 1) a case of peripheral corneal edema in the setting of iridocorneal endothelial syndrome after 4 weeks on netarsudil, 2) a case of corneal edema in the setting of early penetrating keratoplasty graft failure after 2-week use of netarsudil, and 3) a case of corneal edema in the setting of chronic penetrating keratoplasty graft failure after 4-week use of netarsudil. Corneal clearance was not observed in a case of corneal edema in the setting of pseudophakic bullous keratopathy from previous complicated intraocular lens exchange surgery with placement of an anterior chamber intraocular lens after the use of netarsudil for 12 weeks.
CONCLUSIONS: Addition of topical rho-kinase inhibitor in the form of netarsudil can result in corneal clearance in a variety of certain cases of endothelial cell dysfunction, not previously documented in the literature.

Entities:  

Year:  2021        PMID: 33269892     DOI: 10.1097/ICO.0000000000002421

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  2 in total

1.  Netarsudil-associated reticular corneal epithelial edema.

Authors:  Jennifer A Tran; Ula V Jurkunas; Jia Yin; Emma C Davies; David A Sola-Del Valle; Teresa C Chen; Michael M Lin
Journal:  Am J Ophthalmol Case Rep       Date:  2022-01-20

Review 2.  New Horizons in the Treatment of Corneal Endothelial Dysfunction.

Authors:  Carlos Rocha-de-Lossada; Rahul Rachwani-Anil; Davide Borroni; José-María Sánchez-González; Raquel Esteves-Marques; Fernando-Luis Soler-Ferrández; Jose-Antonio Gegúndez-Fernández; Vito Romano; Eitan Livny; Marina Rodríguez Calvo-de-Mora
Journal:  J Ophthalmol       Date:  2021-07-09       Impact factor: 1.909

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.